End-stage renal disease: Symptom management and advance care planning

American Family Physician

Volumn 85, Issue 7, 2012, Pages 705-710

  O'connor, Nina R ^a   Corcoran, Amy M ^b  

^a Arkansas Hospice   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; CODEINE; DRONABINOL; EMOLLIENT AGENT; FENTANYL; FLUOXETINE; GABAPENTIN; HALOPERIDOL; HYDROCODONE; HYDROMORPHONE; HYDROXYZINE EMBONATE; MEGESTROL; METHADONE; METOCLOPRAMIDE; MORPHINE; NALTREXONE; NONSTEROID ANTIINFLAMMATORY AGENT; ONDANSETRON; OXYCODONE; PETHIDINE; PREDNISONE; PREGABALIN; SERTRALINE; SILDENAFIL; TEMAZEPAM; TRAMADOL; ZOLPIDEM;

ABDOMINAL PAIN; AGITATION; ANEMIA; ANOREXIA; ARTICLE; BEDTIME DOSAGE; CALCINOSIS; CREATININE CLEARANCE; DELIRIUM; DEPRESSION; DRUG DOSE REDUCTION; DYSPNEA; FATIGUE; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY PAIN; KIDNEY POLYCYSTIC DISEASE; LIFE EXPECTANCY; LOADING DRUG DOSE; MUSCULOSKELETAL PAIN; NAUSEA; NEUROPATHIC PAIN; PAIN; PERIPHERAL NEUROPATHY; PERIPHERAL VASCULAR DISEASE; PRURITUS; QUALITY OF LIFE; RESUSCITATION; SEXUAL DYSFUNCTION; SLEEP DISORDER;

ADVANCE CARE PLANNING; AGE FACTORS; CARDIOPULMONARY RESUSCITATION; HUMANS; KIDNEY FAILURE, CHRONIC; PAIN; PAIN MANAGEMENT; RENAL DIALYSIS;

EID: 84859119465     PISSN: 0002838X     EISSN: 15320650     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. U.S. Renal Data System. USRDS 2011 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda, Md.: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2011.
2. Murray AM. Cognitive impairment in the aging dialysis and chronic kidney disease populations: an occult burden. Adv Chronic Kidney Dis. 2008;15 (2):123-132.
3. Yong DS, Kwok AO, Wong DM, Suen MH, Chen WT, Tse DM. Symptom burden and quality of life in end-stage renal disease: a study of 179 patients on dialysis and palliative care. Palliat Med. 2009; 23 (2): 111-119.
4. Saini T, Murtagh FE, Dupont PJ, McKinnon PM, Hatfeld P, Saunders Y. Comparative pilot study of symptoms and quality of life in cancer patients and patients with end stage renal disease. Palliat Med. 2006;20(6):631-636.
5. Claxton RN, Blackhall L, Weisbord SD, Holley JL. Undertreatment of symptoms in patients on maintenance hemodialysis. J Pain Symptom Manage. 2010;39(2):211-218.
6. Douglas C, Murtagh FE, Chambers EJ, Howse M, Ellershaw J. Symptom management for the adult patient dying with advanced chronic kidney disease: a review of the literature and development of evidence-based guidelines by a United Kingdom Expert Consensus Group. Palliat Med. 2009;23(2):103-110.
7. Davison SN. Pain in hemodialysis patients: prevalence, cause, severity, and management. Am J Kidney Dis. 2003;42 (6):1239-1247.
8. Cohen LM, Moss AH, Weisbord SD, Germain MJ. Renal palliative care. J Palliat Med. 2006;9(4):977-992.
9. Pastan S, Bailey J. Dialysis therapy. N Engl J Med. 1998;338 (20):1428-1437.
10. Murtagh FE, Chai MO, Donohoe P, Edmonds PM, Higginson IJ. The use of opioid analgesia in end-stage renal disease patients managed without dialysis: recommendations for practice. J Pain Palliat Care Pharma-cother. 2007; 21 (2): 5-16.
11. Dean M. Opioids in renal failure and dialysis patients. J Pain Symptom Manage. 2004;28(5):497-504.
12. Aronoff GR, Berns JS, Brier ME, et al. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults. 4th ed. Philadelphia, Pa.: American College of Physicians; 1999.
13. Landefeld CS, Steinman MA. The Neurontin legacy-marketing through misinformation and manipulation. N Engl J Med. 2009;360(2):103-106.
14. Neurontin (gabapentin) [prescribing information]. New York, NY: Pfzer; 2011. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=52049. Accessed September 16, 2011.
15. Lyrica (pregabalin) [prescribing information]. New York, NY: Pfzer; 2011. http://labeling.pfzer.com/ShowLabeling.aspx?id=561. Accessed September 16, 2011.
16. Murtagh FE, Addington-Hall JM, Edmonds PM, et al. Symptoms in advanced renal disease: a cross-sectional survey of symptom prevalence in stage 5 chronic kidney disease managed without dialysis. J Palliat Med. 2007;10 (6):1266-1276.
17. Murtagh FE, Addington-Hall JM, Donohoe P, Higginson IJ. Symptom management in patients with established renal failure managed without dialysis. EDTNA ERCA J. 2006;32(2):93-98.
18. Murtagh FE, Murphy E, Shepherd KA, Donohoe P, Edmonds PM. End-of-life care in end-stage renal disease: renal and palliative care. Br J Nurs. 2006;15 (1):8-11.
19. Critchley P, Plach N, Grantham M, et al. Efficacy of haloperidol in the treatment of nausea and vomiting in the palliative patient: a systematic review. J Pain Symptom Manage. 2001;22(2):631-634.
20. Cohen LM, Tessier EG, Germain MJ, Levy NB. Update on psychotropic medication use in renal disease. Psychosomatics. 2004;45(1):34-48.
21. Galla JH; Renal Physicians Association; American Society of Nephrol-ogy. Clinical practice guideline on shared decision-making in the appropriate initiation of and withdrawal from dialysis [published correction appears in J Am Soc Nephrol. 2000;11(9):2 p following 1788]. J Am Soc Nephrol. 2000;11(7):1340-1342.
22. Brunori G, Viola BF, Parrinello G, et al. Efficacy and safety of a very-low-protein diet when postponing dialysis in the elderly: a prospective randomized multicenter controlled study. Am J Kidney Dis. 2007;49(5):569-580.
23. Smith C, Da Silva-Gane M, Chandna S, Warwicker P, Greenwood R, Farrington K. Choosing not to dialyse: evaluation of planned non-dialytic management in a cohort of patients with end-stage renal failure. Nephron Clin Pract. 2003;95(2):c40-c46.
24. Wong CF, McCarthy M, Howse ML, Williams PS. Factors affecting survival in advanced chronic kidney disease patients who choose not to receive dialysis [published correction appears in Ren Fail. 2008;30(3):343]. Ren Fail. 2007;29(6):653-659.
25. Murtagh FE, Addington-Hall JM, Higginson IJ. End-stage renal disease: a new trajectory of functional decline in the last year of life. J Am Geriatr Soc. 2011;59(2):304-308.
26. Murtagh FE, Marsh JE, Donohoe P, Ekbal NJ, Sheerin NS, Harris FE. Dialysis or not? A comparative survival study of patients over 75 years with chronic kidney disease stage 5. Nephrol Dial Transplant. 2007;22(7):1955-1962.
27. Cooper BA, Branley P, Bulfone L, et al.; IDEAL Study. A randomized, controlled trial of early versus late initiation of dialysis. N Engl J Med. 2010;363(7):609-619.
28. Moss AH. Improving end-of-life care for dialysis patients. Am J Kidney Dis. 2005;45(1):209-212.
29. Moss AH, Holley JL, Upton MB. Outcomes of cardiopulmonary resuscitation in dialysis patients. J Am Soc Nephrol. 1992;3 (6):1238-1243.
30. Moss AH, Hozayen O, King K, Holley JL, Schmidt RJ. Attitudes of patients toward cardiopulmonary resuscitation in the dialysis unit. Am J Kidney Dis. 2001;38(4):847-852.
31. Holley JL. Advance care planning in elderly chronic dialysis patients. Int Urol Nephrol. 2003;35(4):565-568.
32. Holley JL, Hines SC, Glover JJ, Babrow AS, Badzek LA, Moss AH. Failure of advance care planning to elicit patients' preferences for withdrawal from dialysis. Am J Kidney Dis. 1999;33(4):688-693.
33. Davison SN. End-of-life care preferences and needs: perceptions of patients with chronic kidney disease. Clin J Am Soc Nephrol. 2010;5(2):195-204.
34. Bartlow B. In search of an advance directive that works for end-stage renal disease patients. Hemodial Int. 2006;10(suppl 2):S38-S45.
35. Thompson KF, Bhargava J, Bachelder R, Bova-Collis R, Moss AH. Hospice and ESRD: knowledge defcits and underutilization of program benefts. Nephrol Nurs J. 2008;35(5):461-466.
36. Murray AM, Arko C, Chen SC, Gilbertson DT, Moss AH. Use of hospice in the United States dialysis population. Clin J Am Soc Nephrol. 2006;1(6):1248-1255.